Hamid Reza Khorram Khorshid | Breast cancer | Research Excellence Distinction Award

Published on by Academic Achievements

Prof Dr. Hamid Reza Khorram Khorshid | Breast cancer | Research Excellence Distinction Award

Professor | Hope Generation Foundation  | Iran

Short Biography 📜

Dr. Hamid Reza Khorram Khorshid, a distinguished Medical Geneticist, serves as a Professor at the University of Social Welfare and Rehabilitation Sciences (USWR) in Tehran, Iran. His extensive research focuses on complex genetic disorders, including neurodegenerative diseases and congenital anomalies, emphasizing the role of medical genetics in public health.

Profile:

SCOPUS

Education 🎓

Dr. Khorram Khorshid completed his MD from Tehran University of Medical Sciences in 1990, followed by an MPH in Public Health in 1999. He pursued further studies in Genetics, earning a Post Graduate Diploma from the University of Leicester in 2000 and a PhD in Genetics in 2003.

Experience 🌐

Since 2003, Dr. Khorram Khorshid has been integral to the Genetics Research Center at USWR, progressing from Assistant to Associate Professor before attaining full Professorship in 2013. He also holds leadership roles at the Hope Generation Foundation, serving as Deputy of Research and Technology and heading the Personalized Medicine and Proteogenomics Research Center.

Research Interests 🔬

Dr. Khorram Khorshid’s research spans various facets of medical genetics, with a keen interest in neurodegenerative diseases such as Alzheimer’s and Multiple Sclerosis, congenital anomalies like cleft palate/lip, and genetic contributions to male and female infertility. His work underscores the intersection of genetics with public health initiatives.

Awards 🏆

Dr. Khorram Khorshid has received recognition for his contributions to medical genetics and public health, though specific awards are not detailed in the provided information.

Publications 📚

Survival models and risk factors of breastfeeding in urban and rural areas of Takestan, introducing survival analysis, Iranian Journal of Public Health, 1999, cited by 12 articles

Characterization of the human secreted phosphoprotein 24 gene (SPP2) and comparison of the protein sequence in nine species, Matrix Biology, 2004, cited by 34 articles

The Comparison of the Effectiveness of a Modified Conformation Sensitive Gel Electrophoresis with Denaturing High-Performance Liquid Chromatography, Iranian Biomedical Journal, 2008

Detection of Mycoplasma DNA in rheumatoid arthritis patients serum by PCR, Journal of Medical Council of Islamic Republic of Iran, 2007, cited by 18 articles

Evaluation of acute and sub-chronic toxicity of Semelil (ANGIPARSTM), a new phytotherapeutic drug for wound healing in rodents, Daru Journal of Pharmaceutical Sciences, 2008

Clinical application of oral form of ANGIPARSTM and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial, Daru Journal of Pharmaceutical Sciences, 2008

Topical application of Semelil (ANGIPARSTM) in treatment of pressure ulcers: A randomized clinical trial, Daru Journal of Pharmaceutical Sciences, 2008

Hepatoprotective effects of Setarud against carbon tetrachloride-induced liver injury in rats, Indian Journal of Gastroenterology, 2008

 

Navdeep Dehar | Oncology | Excellence in Research

Published on by Academic Achievements

Dr.Navdeep Dehar | Oncology | Excellence in Research

Medical Oncologist Queens University Canada

Navdeep Dehar MBBS MD MBT FRCPC is an Assistant Professor in the Department of Oncology at Queen’s University and a Clinician Investigator & Medical Oncologist at the Cancer Centre of Southeastern Ontario. Additionally, he serves as a Precision Medicine Research Fellow at the Canadian Cancer Trials Group. With extensive training and experience in oncology, pharmacology, and biomedical technology, Dr. Dehar has made significant contributions to cancer research and clinical practice.

Profile

Scopus

Education

🎓 Education:

  • Subspecialty Training in Medical Oncology (2021-2023) – Queen’s University, Kingston, ON
  • Residency in Internal Medicine (2018-2021) – Cumming School of Medicine, University of Calgary, Alberta
  • Master of Biomedical Technology (MBT) (2012-2013) – University of Calgary, Alberta
  • Residency in Pharmacology – Doctor of Medicine (MD) (2005-2008) – Baba Farid University of Health Sciences, India
  • Bachelor of Medicine and Bachelor of Surgery (MBBS) (1998-2002) – Dayanand Medical College and Hospital, Baba Farid University of Health Sciences, India

Experience

💼 Experience:

  • Clinician Investigator & Staff Medical Oncologist (Locum) (July 2023 – present) – Cancer Centre of Southeastern Ontario, Kingston, ON
  • Assistant Professor of Medical Oncology (July 2023 – present) – Department of Medical Oncology, Queen’s University, Kingston, ON
  • Precision Medicine Research Fellow (October 2023 to September 2024) – Canadian Clinical Trials Group (CCTG), Kingston, ON
  • Medical Oncology Resident (2021-2023) – Queen’s University, Kingston, ON
  • Internal Medicine Resident (2018-2021) – University of Calgary, AB
  • Clinical Research Consultant (2013-2018) – GNR Biomedical Inc.

Research Interests

🔬 Research Interests:

  • Gastrointestinal Cancers
  • Neuroendocrine Tumors
  • Breast Cancer
  • Precision Oncology
  • Artificial Intelligence/Machine Learning in Oncology
  • Quality Improvement in Clinical Trials
  • Cancer Therapeutics with a Focus on Pharmacogenomics
  • Patient and Physician Education Initiatives
  • Global Oncology with a Focus on Quality Improvement

Awards

🏆 Awards:

  • Scholarship for Training in Lung Cancer (2023) – Canadian Lung Cancer Conference, Vancouver
  • Award of Appreciation for Extraordinary Contribution to Resident Redeployment Initiative during COVID Pandemic (2022) – Queen’s University, Kingston
  • Dr. Chirag Shah International Medical Graduate Award Recipient (2018) – Alberta International Medical Graduate Program, University of Calgary
  • Young Scientist Award (2008) – Sant Longowal Institute of Science and Technology, India

Publications

📚 Publications:

  • Dehar N, Gupta A, Singh G. “Comparative Study of the Efficacy and Safety of Ketorolac Tromethamine 0.5% Ophthalmic Solution and Diclofenac Sodium 0.1% Ophthalmic Solution in Patients of Acute Seasonal Allergic Conjunctivitis.” Int J Appl Basic Med Res. 2012 Jan-Jun; 2(1): 25–30. doi:10.4103/2229-516X.96799
  • Miriam Mutebi, Navdeep Dehar, Leticia M. Nogueira, Kewei Shi, K. Robin Yabroff,
    and Bishal Gyawali. Cancer Groundshot: Building a Robust Cancer Control Platform in
    Addition To Launching the Cancer Moonshot. American Society of Clinical Oncology
    Educational Book 2022:42, 1-16